S&P 500   3,858.37 (+0.17%)
DOW   31,220.52 (+0.10%)
QQQ   324.78 (+0.31%)
AAPL   135.22 (+2.42%)
MSFT   223.32 (-0.45%)
FB   271.13 (+1.36%)
GOOGL   1,929.50 (+2.63%)
AMZN   3,317.05 (+1.64%)
TSLA   846.85 (-0.42%)
NVDA   542.01 (+1.38%)
BABA   259.98 (-2.08%)
CGC   33.36 (-0.80%)
GE   11.25 (-1.23%)
MU   83.06 (-0.53%)
AMD   89.94 (+1.34%)
NIO   56.62 (-1.89%)
T   28.84 (-0.41%)
F   11.25 (+3.59%)
ACB   11.11 (-3.73%)
BA   208.22 (-1.53%)
DIS   171.55 (-1.20%)
NFLX   579.69 (-1.13%)
GILD   67.12 (-1.28%)
S&P 500   3,858.37 (+0.17%)
DOW   31,220.52 (+0.10%)
QQQ   324.78 (+0.31%)
AAPL   135.22 (+2.42%)
MSFT   223.32 (-0.45%)
FB   271.13 (+1.36%)
GOOGL   1,929.50 (+2.63%)
AMZN   3,317.05 (+1.64%)
TSLA   846.85 (-0.42%)
NVDA   542.01 (+1.38%)
BABA   259.98 (-2.08%)
CGC   33.36 (-0.80%)
GE   11.25 (-1.23%)
MU   83.06 (-0.53%)
AMD   89.94 (+1.34%)
NIO   56.62 (-1.89%)
T   28.84 (-0.41%)
F   11.25 (+3.59%)
ACB   11.11 (-3.73%)
BA   208.22 (-1.53%)
DIS   171.55 (-1.20%)
NFLX   579.69 (-1.13%)
GILD   67.12 (-1.28%)
S&P 500   3,858.37 (+0.17%)
DOW   31,220.52 (+0.10%)
QQQ   324.78 (+0.31%)
AAPL   135.22 (+2.42%)
MSFT   223.32 (-0.45%)
FB   271.13 (+1.36%)
GOOGL   1,929.50 (+2.63%)
AMZN   3,317.05 (+1.64%)
TSLA   846.85 (-0.42%)
NVDA   542.01 (+1.38%)
BABA   259.98 (-2.08%)
CGC   33.36 (-0.80%)
GE   11.25 (-1.23%)
MU   83.06 (-0.53%)
AMD   89.94 (+1.34%)
NIO   56.62 (-1.89%)
T   28.84 (-0.41%)
F   11.25 (+3.59%)
ACB   11.11 (-3.73%)
BA   208.22 (-1.53%)
DIS   171.55 (-1.20%)
NFLX   579.69 (-1.13%)
GILD   67.12 (-1.28%)
S&P 500   3,858.37 (+0.17%)
DOW   31,220.52 (+0.10%)
QQQ   324.78 (+0.31%)
AAPL   135.22 (+2.42%)
MSFT   223.32 (-0.45%)
FB   271.13 (+1.36%)
GOOGL   1,929.50 (+2.63%)
AMZN   3,317.05 (+1.64%)
TSLA   846.85 (-0.42%)
NVDA   542.01 (+1.38%)
BABA   259.98 (-2.08%)
CGC   33.36 (-0.80%)
GE   11.25 (-1.23%)
MU   83.06 (-0.53%)
AMD   89.94 (+1.34%)
NIO   56.62 (-1.89%)
T   28.84 (-0.41%)
F   11.25 (+3.59%)
ACB   11.11 (-3.73%)
BA   208.22 (-1.53%)
DIS   171.55 (-1.20%)
NFLX   579.69 (-1.13%)
GILD   67.12 (-1.28%)
Log in
NYSE:ZTS

Zoetis Stock Forecast, Price & News

$163.24
-0.12 (-0.07 %)
(As of 01/21/2021 10:03 AM ET)
Add
Compare
Today's Range
$162.47
Now: $163.24
$163.61
50-Day Range
$157.07
MA: $162.38
$169.39
52-Week Range
$90.14
Now: $163.24
$176.64
Volume4,227 shs
Average Volume1.78 million shs
Market Capitalization$77.58 billion
P/E Ratio48.44
Dividend Yield0.49%
Beta0.71
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. It also provides other pharmaceutical products, which comprise pain and sedation, antiemetic, reproductive, and oncology products; Dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives that offer medicines to livestock. In addition, the company offers portable blood and urine analysis systems, and point-of-care diagnostic products, including instruments and reagents, rapid immunoassay tests, reference laboratory kits, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision livestock farming. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.
Zoetis logo

MarketRank

Overall MarketRank

1.82 out of 5 stars

Medical Sector

137th out of 1,928 stocks

Pharmaceutical Preparations Industry

65th out of 774 stocks

Analyst Opinion: 1.3Community Rank: 3.2Dividend Strength: 1.7Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP98978V10
Phone973-822-7000
Employees10,600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.26 billion
Cash Flow$4.64 per share
Book Value$5.69 per share

Profitability

Net Income$1.50 billion

Miscellaneous

Market Cap$77.58 billion
Next Earnings Date2/16/2021 (Confirmed)
OptionableOptionable
$163.24
-0.12 (-0.07 %)
(As of 01/21/2021 10:03 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZTS News and Ratings via Email

Sign-up to receive the latest news and ratings for ZTS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Zoetis (NYSE:ZTS) Frequently Asked Questions

How has Zoetis' stock been impacted by Coronavirus?

Zoetis' stock was trading at $130.27 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ZTS shares have increased by 25.4% and is now trading at $163.36.
View which stocks have been most impacted by COVID-19
.

Is Zoetis a buy right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 8 hold ratings, 8 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Zoetis stock.
View analyst ratings for Zoetis
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Zoetis?

Wall Street analysts have given Zoetis a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Zoetis wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Thomas Greco's approval rating as Zoetis' CEO?

538 employees have rated Zoetis CEO Thomas Greco on Glassdoor.com. Thomas Greco has an approval rating of 63% among Zoetis' employees. This puts Thomas Greco in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Zoetis' next earnings date?

Zoetis is scheduled to release its next quarterly earnings announcement on Tuesday, February 16th 2021.
View our earnings forecast for Zoetis
.

How can I listen to Zoetis' earnings call?

Zoetis will be holding an earnings conference call on Tuesday, February 16th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Zoetis' earnings last quarter?

Zoetis Inc. (NYSE:ZTS) announced its earnings results on Thursday, November, 5th. The company reported $1.10 earnings per share for the quarter, topping analysts' consensus estimates of $0.91 by $0.19. The business had revenue of $1.79 billion for the quarter, compared to the consensus estimate of $1.63 billion. Zoetis had a return on equity of 63.89% and a net margin of 25.50%. The business's revenue was up 12.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.94 earnings per share.
View Zoetis' earnings history
.

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis announced a quarterly dividend on Wednesday, December 9th. Shareholders of record on Wednesday, January 20th will be given a dividend of $0.25 per share on Monday, March 1st. This represents a $1.00 annualized dividend and a dividend yield of 0.61%. The ex-dividend date is Tuesday, January 19th. This is an increase from Zoetis's previous quarterly dividend of $0.20.
View Zoetis' dividend history
.

Is Zoetis a good dividend stock?

Zoetis pays an annual dividend of $0.80 per share and currently has a dividend yield of 0.49%. Zoetis does not yet have a strock track record of dividend growth. The dividend payout ratio of Zoetis is 21.98%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Zoetis will have a dividend payout ratio of 19.42% next year. This indicates that Zoetis will be able to sustain or increase its dividend.
View Zoetis' dividend history.

What guidance has Zoetis issued on next quarter's earnings?

Zoetis issued an update on its FY20 earnings guidance on Thursday, November, 5th. The company provided earnings per share guidance of $3.76-3.81 for the period, compared to the Thomson Reuters consensus estimate of $3.63. The company issued revenue guidance of $6.55-6.625 billion, compared to the consensus revenue estimate of $6.43 billion.

What price target have analysts set for ZTS?

17 brokers have issued twelve-month price targets for Zoetis' shares. Their forecasts range from $126.00 to $191.00. On average, they expect Zoetis' stock price to reach $161.14 in the next year. This suggests that the stock has a possible downside of 1.4%.
View analysts' price targets for Zoetis
or view Wall Street analyst' top-rated stocks.

Are investors shorting Zoetis?

Zoetis saw a increase in short interest in December. As of December 31st, there was short interest totaling 3,670,000 shares, an increase of 16.1% from the December 15th total of 3,160,000 shares. Based on an average daily trading volume, of 1,730,000 shares, the days-to-cover ratio is currently 2.1 days. Approximately 0.8% of the shares of the stock are short sold.
View Zoetis' Short Interest
.

Who are some of Zoetis' key competitors?

What other stocks do shareholders of Zoetis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zoetis investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Hawkins (HWKN), Aegean Marine Petroleum Network (ANW), Athabasca Oil Co. (ATH.TO) (ATH), Micron Technology (MU), Accenture (ACN) and Transocean (RIG).

Who are Zoetis' key executives?

Zoetis' management team includes the following people:
  • Ms. Kristin C. Peck, CEO & Director (Age 49, Pay $1.53M)
  • Mr. Glenn C. David, Exec. VP & CFO (Age 48, Pay $1.52M)
  • Mr. Juan Ramón Alaix, Advisor & Director (Age 69, Pay $3.42M)
  • Dr. Catherine A. Knupp, Exec. VP and Pres of R&D (Age 59, Pay $1.51M)
  • Ms. Roxanne Lagano, Exec. VP and Chief HR Officer & Global Operations (Age 55)
  • Ms. Wafaa Mamilli, Exec. VP and Chief Information & Digital Officer (Age 53)
  • Mr. Steven Frank, VP of Investor Relations
  • Ms. Heidi C. Chen, Exec. VP, Gen. Counsel & Corp. Sec. (Age 53)
  • Mr. William Price, VP & Chief Communications Officer
  • Mr. Roman Trawicki, Exec. VP and Pres of Global Manufacturing & Supply (Age 56)

What is Zoetis' stock symbol?

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

Who are Zoetis' major shareholders?

Zoetis' stock is owned by many different institutional and retail investors. Top institutional shareholders include Ardevora Asset Management LLP (0.07%), AMI Asset Management Corp (0.06%), DNB Asset Management AS (0.06%), Gofen & Glossberg LLC IL (0.05%), Manning & Napier Group LLC (0.05%) and Atalanta Sosnoff Capital LLC (0.05%). Company insiders that own Zoetis stock include Andrew Fenton, Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Linda Rhodes, Roman Trawicki, Roxanne Lagano and Willie M Reed.
View institutional ownership trends for Zoetis
.

Which major investors are selling Zoetis stock?

ZTS stock was sold by a variety of institutional investors in the last quarter, including Sonora Investment Management LLC, DAVENPORT & Co LLC, Hexavest Inc., Stack Financial Management Inc, Windward Capital Management Co. CA, Ardevora Asset Management LLP, AMI Asset Management Corp, and Autus Asset Management LLC. Company insiders that have sold Zoetis company stock in the last year include Catherine A Knupp, Glenn David, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Linda Rhodes, Roman Trawicki, Roxanne Lagano, and Willie M Reed.
View insider buying and selling activity for Zoetis
or view top insider-selling stocks.

Which major investors are buying Zoetis stock?

ZTS stock was bought by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, DNB Asset Management AS, Farmers & Merchants Investments Inc., Baldwin Brothers Inc. MA, IFM Investors Pty Ltd, Bennett Selby Investments LP, Louisiana State Employees Retirement System, and MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH.
View insider buying and selling activity for Zoetis
or or view top insider-buying stocks.

How do I buy shares of Zoetis?

Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zoetis' stock price today?

One share of ZTS stock can currently be purchased for approximately $163.36.

How big of a company is Zoetis?

Zoetis has a market capitalization of $77.64 billion and generates $6.26 billion in revenue each year. The company earns $1.50 billion in net income (profit) each year or $3.64 on an earnings per share basis. Zoetis employs 10,600 workers across the globe.

What is Zoetis' official website?

The official website for Zoetis is www.zoetis.com.

How can I contact Zoetis?

Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company can be reached via phone at 973-822-7000 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.